Array BioPharma (ARRY)
This is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. This stock is trading up 6.2% to $3.59 in recent trading.
Today's Range: $3.36-$3.63
52-Week Range: $1.58-$6.17Volume: 1.27 million Three-Month Average Volume: 1.08 million From a technical perspective, ARRY is bouncing higher here right off some near-term support at $3.30 with above-average volume. This stock has been downtrending badly for the last two months, with shares falling from a high of $6.17 to its recent low of $3.25. During that downtrend, shares of ARRY were consistently making lower highs and lower lows, which is bearish technical price action. That said, the stock has now started to rebound and move within range of triggering a near-term breakout trade. That trade will hit once ARRY manages to take out some near-term overhead resistance at $3.59 to $3.63. Traders should now look for long-biased trades in ARRY as long as it's trending above $3.25, and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.08 million shares. If that breakout trigger soon, then ARRY will set up to re-fill a previous gap down zone that started above $4. If that gap gets filled, then ARRY could easily re-test its 50-day at $4.68 in the near future. To see more stocks that are making notable moves higher today, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr. -- Written by Roberto Pedone in Winderemere, Fla.
Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV